Ascaltis submits an IND application to the US FDA for ASC36_37o FDC, a potential first-in-class once-weekly oral quadruple peptide agonist targeting the amylin receptor, GLP-1R, GIPR and GCGR, for the treatment of obesity. Company announcement - F.
🇺🇸 USA · Map
Ascaltis submits an IND application to the US FDA for ASC36_37o FDC, a potential first-in-class once-weekly oral quadruple peptide agonist targeting the amylin receptor, GLP-1R, GIPR and GCGR, for the treatment of obesity. Company announcement - F.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in